Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam−β-Lactamase Inhibitor Combination

著者: Krisztina M. Papp‐Wallace, Christopher R. Bethel, J. Caillon, Melissa D. Barnes, G. Potel, Saralee Bajaksouzian, Joseph Rutter, Amokrane Reghal, Stuart Shapiro, Magdalena A. Taracila, Michael R. Jacobs, Robert A. Bonomo, Cédric Jacqueline - Antimicrobial Agents and Chemotherapy 2019 被引用: 118

Impeding, as well as reducing, the burden of antimicrobial resistance in Gram-negative pathogens is an urgent public health endeavor. Our current antibiotic armamentarium is dwindling, while major resistance determinants (e.g., extended-spectrum β-lactamases [ESBLs]) continue to evolve and disseminate around the world.